Businessweek Archives

Merck's Thinning Management


Top of the News

MERCK'S THINNING MANAGEMENT

MARTIN J. WYGOD

Sold Medco to Merck for $6.6 billion last year. Felt he had Vagelos' backing but quit the race--and then Merck--because it demanded a "total commitment" he couldn't provide. A long shot with the board anyway.

JOHN L. ZABRISKIE

Merck's head of manufacturing left in December for the top job at rival Upjohn. A lifer at Merck, he seemed to have all the right credentials--but had been passed over when Markham was chosen president.

RICHARD J. MARKHAM

Elevated in late 1992 to president and heir apparent by Vagelos, he quit the job, citing personal reasons, after only seven months. The hard-charging sales executive, then 42, became president at Marion Merrell Dow.

...And other important players may follow

JUDY C. LEWENT

Merck's chief financial officer was widely rumored to be presidential timber. She will be courted intensely by headhunters, and could jump for the right opportunity--maybe back to Wall Street.

EDWARD M. SCOLNICK

The brilliant head of R&D was seen by many as Roy Vagelos' natural successor--until his gruff ways called his personnel skills into question. He may want to stay on until drugs developed during his watch debut.

JERRY T. JACKSON

Merck's worldwide sales head got a hefty golden handcuffs deal after Wygod took over much of the sales force. Jackson will likely be on headhunters' short lists, though he talks longingly of retiring to Texas.


Tim Cook's Reboot
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus